{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:54:55Z","timestamp":1794048895118,"version":"4.8.0"},"reference-count":194,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bras Pneumol."],"abstract":"<jats:p>Lymphangioleiomyomatosis (LAM) is a rare disease, characterized as a low-grade neoplasm with metastatic potential that mainly affects women of reproductive age, in which there is proliferation of atypical smooth muscle cells (LAM cells) and formation of diffuse pulmonary cysts. It can occur in a sporadic form or in combination with tuberous sclerosis complex. In recent decades, a number of advances have been made in the understanding of the pathophysiology and management of LAM, leading to improvements in its prognosis: identification of the main genetic aspects and the role of the mechanistic target of rapamycin (mTOR) pathway; relationship with hormonal factors, mainly estrogen; characterization of pulmonary and extrapulmonary manifestations in imaging studies; identification and importance in the diagnosis of VEGF-D; a systematic diagnostic approach, often without the need for lung biopsy; use of and indications for the use of mTOR inhibitors, mainly sirolimus, for pulmonary and extrapulmonary manifestations; pulmonary rehabilitation and the management of complications such as pneumothorax and chylothorax; and the role of and indications for lung transplantation. To date, no Brazilian recommendations for a comprehensive approach to the disease have been published. This document is the result of a non-systematic review of the literature, carried out by 12 pulmonologists, a radiologist, and a pathologist, which aims to provide an update of the most important topics related to LAM, mainly to its diagnosis, treatment, and follow-up, including practical and multidisciplinary aspects of its management.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20240378","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T20:46:09Z","timestamp":1738788369000},"page":"e20240378","source":"Crossref","is-referenced-by-count":3,"title":["Brazilian Thoracic Association recommendations for the management of lymphangioleiomyomatosis"],"prefix":"10.36416","author":[{"given":"Bruno","family":"Guedes Baldi1","sequence":"first","affiliation":[{"name":"1. Divisao de Pneumologia, Instituto do Coracao \u2013 InCor \u2013 Hospital das Clinicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo \u2013 HCFMUSP \u2013 S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Henrique","family":"Ramos Feitosa2","sequence":"additional","affiliation":[{"name":"2. Hospital da Asa Norte, Bras\u00edlia (DF) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adalberto","family":"Sperb Rubin3","sequence":"additional","affiliation":[{"name":"3. Servi\u00e7o de Pneumologia, Pavilh\u00e3o Pereira Filho, Santa Casa de Porto Alegre, Porto Alegre (RS) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Franco Amaral1","sequence":"additional","affiliation":[{"name":"1. Divisao de Pneumologia, Instituto do Coracao \u2013 InCor \u2013 Hospital das Clinicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo \u2013 HCFMUSP \u2013 S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Salim Gon\u00e7alves Freitas4","sequence":"additional","affiliation":[{"name":"4. Hospital AC Camargo, S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udia","family":"Henrique da Costa5","sequence":"additional","affiliation":[{"name":"5. Universidade do Estado do Rio de Janeiro, Rio de Janeiro (RJ) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane","family":"Viana Mancuzo6","sequence":"additional","affiliation":[{"name":"6. Servi\u00e7o de Pneumologia e Cirurgia Tor\u00e1cica, Hospital das Cl\u00ednicas, Universidade Federal de Minas Gerais, Belo Horizonte (MG) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen Caroline","family":"Toledo do Nascimento7","sequence":"additional","affiliation":[{"name":"7. Departamento de Patologia, Hospital das Clinicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo \u2013 HCFMUSP \u2013 S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Sponholz Araujo8","sequence":"additional","affiliation":[{"name":"8. Divis\u00e3o de Pneumologia, Hospital de Cl\u00ednicas, Universidade Federal do Paran\u00e1, Curitiba (PR) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Jorge","family":"Jac\u00f3 Rocha9","sequence":"additional","affiliation":[{"name":"9. Hospital de Messejana, Fortaleza (CE) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rodrigues de Oliveira1","sequence":"additional","affiliation":[{"name":"1. Divisao de Pneumologia, Instituto do Coracao \u2013 InCor \u2013 Hospital das Clinicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo \u2013 HCFMUSP \u2013 S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Senna Galv\u00e3o10","sequence":"additional","affiliation":[{"name":"10. Hospital Universit\u00e1rio Professor Edgar Santos, Universidade Federal da Bahia, Salvador (BA) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Paulo","family":"Teixeira e Silva Torres11","sequence":"additional","affiliation":[{"name":"11. Hospital Israelita Albert Einstein, Goi\u00e2nia (GO) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Roberto","family":"Ribeiro Carvalho1","sequence":"additional","affiliation":[{"name":"1. Divisao de Pneumologia, Instituto do Coracao \u2013 InCor \u2013 Hospital das Clinicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo \u2013 HCFMUSP \u2013 S\u00e3o Paulo (SP) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22288","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"ref0","unstructured":"REFERENCES"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"1.           McCormack FX, Travis WD, Colby TV, Henske EP, Moss J. Lymphangioleiomyomatosis: calling it what is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med. 2012;186(12):1210-2. https:\/\/doi.org\/10.1164\/rccm.201205-0848OE","DOI":"10.1164\/rccm.201205-0848oe"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"2.           McCarthy C, Gupta N, Johnson SR, Yu JJ, McCormack FX. Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. Lancet Respir Med. 2021;9(11):1313-27. https:\/\/doi.org\/10.1016\/S2213-2600(21)00228-9","DOI":"10.1016\/s2213-2600(21)00228-9"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"3.           Oliveira MR, Wanderley M, Freitas CSG, Kairalla RA, Chate RC, Amaral AF, et al. Clinical, tomographic and functional comparison of sporadic and tuberous sclerosis complex-associated forms of lymphangioleiomyomatosis: a retrospective cohort study. ERJ Open Res. 2024;10(2):00759-2023. https:\/\/doi.org\/10.1183\/23120541.00759-2023","DOI":"10.1183\/23120541.00759-2023"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"4.           Harari S, Torre O, Cassandro R, Moss J. The changing face of a rare disease: lymphangioleiomyomatosis. Eur Respir J. 2015;46(5):1471-85. https:\/\/doi.org\/10.1183\/13993003.00412-2015","DOI":"10.1183\/13993003.00412-2015"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"5.           Northrup H, Aronow ME, Bebin EM, Bissler J, Darling TN, de Vries PJ, et al; International Tuberous Sclerosis Complex Consensus Group. Updated International Tuberous Sclerosis Complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol. 2021;123:50-66. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2021.07.011","DOI":"10.1161\/jaha.114.001493"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"6.           Harknett EC, Chang WYC, Byrnes S, Johnson J, Lazor R, Cohen MM, et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM. 2011;104(11):971-9. https:\/\/doi.org\/10.1093\/qjmed\/hcr116","DOI":"10.1093\/qjmed\/hcr116"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"7.           Johnson SR, Tattersfield AE. Clinical experience of lymphangioleiomyomatosis in the UK. Thorax. 2000;55(12):1052-7. https:\/\/doi.org\/10.1136\/thorax.55.12.1052","DOI":"10.1136\/thorax.55.12.1052"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"8.           Urban T, Lazor R, Lacronique J, Murris M, Labrune S, Valeyre D, et al. Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d\u2019Etudes et de Recherche sur les Maladies \u201cOrphelines\u201d Pulmonaires (GERM\u201dO\u201dP) Medicine (Baltimore). 1999;78(5):321-7. https:\/\/doi.org\/10.1097\/00005792-199909000-00004","DOI":"10.1097\/00005792-199909000-00004"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"9.           Kelly J, Moss J. Lymphangioleiomyomatosis. Am J Med Sci. 2001;321(1):17-25. https:\/\/doi.org\/10.1097\/00000441-200101000-00004","DOI":"10.1097\/00000441-200101000-00004"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"10.        Lynn E, Forde SH, Franciosi AN, Bendstrup E, Veltkamp M, Wind AE, et al. Updated Prevalence of Lymphangioleiomyomatosis in Europe. Am J Respir Crit Care Med. 2024;209(4):456-9. https:\/\/doi.org\/10.1164\/rccm.202310-1736LE","DOI":"10.1164\/rccm.202310-1736le"},{"key":"ref11","unstructured":"11.        The LAM Foundation [homepage on the Internet]. Cincinnati: The Lam Foundation; c2024 [cited 2024 Aug 31]. Available from: https:\/\/www.thelamfoundation.org\/Newly-Diagnosed\/Learning-About-Lam\/About-LAM"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"12.        Ryu JH, Moss J, Beck GJ, Lee JC, Brown KK, Chapman JT et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006;173(1):105-11. https:\/\/doi.org\/10.1164\/rccm.200409-1298OC","DOI":"10.1164\/rccm.200409-1298oc"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"13.        Cudzilo CJ, Szczesniak RD, Brody AS, Rattan MS, Krueger DA, Bissler JJ, et al. Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest. 2013;144(2):578-85. https:\/\/doi.org\/10.1378\/chest.12-2813","DOI":"10.1378\/chest.12-2813"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"14.        Ryu JH, Sykes AM, Lee AS, Burger CD. Cystic lung disease is not uncommon in men with tuberous sclerosis complex. Respir Med. 2012;106(11):1586-90. https:\/\/doi.org\/10.1016\/j.rmed.2012.07.007","DOI":"10.1016\/j.rmed.2012.07.007"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"15.        Muzykewicz DA, Sharma A, Muse V, et al. TSC1 and TSC2 mutations in patients with lymphangioleiomyomatosis and tuberous sclerosis complex. J Med Genet. 2009;46(7):465-8. https:\/\/doi.org\/10.1136\/jmg.2008.065342","DOI":"10.1136\/jmg.2008.065342"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"16.        Krymskaya VP, McCormack FX. Lymphangioleiomyomatosis: a monogenic model of malignancy. Annu Rev Med. 2017;14(68):69-83. https:\/\/doi.org\/10.1146\/annurev-med-050715-104245","DOI":"10.1146\/annurev-med-050715-104245"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"17.        Marom D. Genetics of tuberous sclerosis complex: an update. Childs Nerv Syst. 2020;36(10):2489-96. https:\/\/doi.org\/10.1007\/s00381-020-04726-z","DOI":"10.1007\/s00381-020-04726-z"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"18.        Brentani MM, Carvalho CRR, Saldiva PHN, Pacheco MM, Oshima CTF. Steroid receptors in pulmonary lymphangioleiomyomatosis. Chest. 1984;85(1):96-9. https:\/\/doi.org\/10.1378\/chest.85.1.96","DOI":"10.1378\/chest.85.1.96"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"19.        Tai J, Liu S, Yan X, Huang L, Pan Y, Huang H, et al. Novel developments in the study of estrogen in the pathogenesis and therapeutic intervention of lymphangioleiomyomatosis. Orphanet J Rare Dis. 2024;19(1):236. https:\/\/doi.org\/10.1186\/s13023-024-03239-1","DOI":"10.1186\/s13023-024-03239-1"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"20.        Gupta N, Lee HS, Young LR, Strange C, Moss J, Singer LG, et al. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. Eur Respir J. 2019;53(4):1802066. https:\/\/doi.org\/10.1183\/13993003.02066-2018","DOI":"10.1183\/13993003.02066-2018"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"21.        Mendon\u00e7a LP, Costa NSX, do Nascimento ECT, de Oliveira MR, de Carvalho CRR, Baldi BG, et al. Small airways morphological alterations associated with functional impairment in lymphangioleiomyomatosis. BMC Pulm Med. 2024;24(1):22. https:\/\/doi.org\/10.1186\/s12890-023-02837-2","DOI":"10.1186\/s12890-023-02837-2"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"22.        Johnson SR. Lymphangioleiomyomatosis. Eur Respir J. 2006;27(5):1056-65. https:\/\/doi.org\/10.1183\/09031936.06.00113303","DOI":"10.1183\/09031936.06.00113303"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"23.        Franciosi AN, Gupta N, Murphy DJ, Wikenheiser-Brokamp KA, McCarthy C. Diffuse cystic lung disease: a clinical guide to recognition and management. Chest. 2024; S0012-3692(24)04923-7.  https:\/\/doi.org\/10.1016\/j.chest.2024.08.008","DOI":"10.1016\/j.chest.2024.08.008"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"24.        Rubin R, Baldi BG, Shaw BM, Kingsberg S, Kopras E, Larkin L, et al. Hemoptysis associated with sexual activity in lymphangioleiomyomatosis. Ann Am Thorac Soc. 2024; 21(12):1784-1787. https:\/\/doi.org\/10.1513\/AnnalsATS.202406-616RL","DOI":"10.1513\/annalsats.202406-616rl"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"25.        Freitas CSG, Baldi BG, Araujo MS, Heiden GI, Kairalla RA, Carvalho CRR. Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations. J Bras Pneumol. 2015;41(3):275-80. https:\/\/doi.org\/10.1590\/S1806-37132015000004553","DOI":"10.1590\/s1806-37132015000004553"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"26.        McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, et al. Official American Thoracic Society\/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. Am J Respir Crit Care Med. 2016;194(6):748-61. https:\/\/doi.org\/10.1164\/rccm.201607-1384ST","DOI":"10.1164\/rccm.201607-1384st"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"27.        Cottin V, Blanchard E, Kerjouan M, Lazor R, Reynaud-Gaubert M, Taille C, et al. French recommendations for the diagnosis and management of lymphangioleiomyomatosis. Respir Med Res. 2023;83:101010. https:\/\/doi.org\/10.1016\/j.resmer.2023.101010","DOI":"10.1016\/j.resmer.2023.101010"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"28.        Gupta N, Finlay GA, Kotloff RM, Strange C, Wilson KC, Young LR, et al. Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society\/Japanese Respiratory Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2017;196(10):1337-48. https:\/\/doi.org\/10.1164\/rccm.201709-1965ST","DOI":"10.1164\/rccm.201709-1965st"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"29.        Hayashi T, Kumasaka T, Mitani K, Okada Y, Kondo T, Date H, et al. Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses. Hum Pathol. 2016;50:34-42. https:\/\/doi.org\/10.1016\/j.humpath.2015.11.002","DOI":"10.1016\/j.humpath.2015.11.002"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"30.        Gupta N, Lee HS, Ryu JH, Taveira-DaSilva AM, Beck GJ, Lee JC, et al. The NHLBI LAM Registry: prognostic, physiologic and radiologic biomarkers emerge from a 15-year prospective longitudinal analysis. Chest. 2019;155(2):288-96. https:\/\/doi.org\/10.1016\/j.chest.2018.06.016","DOI":"10.1016\/j.chest.2018.06.016"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"31.        Baldi BG, Albuquerque AL, Pimenta SP, Salge JM, Kairalla RA, Carvalho CR. Exercise performance and dynamic hyperinflation in lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2012;186(4):341-8. https:\/\/doi.org\/10.1164\/rccm.201203-0372OC","DOI":"10.1164\/rccm.201203-0372oc"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"32.        Taveira-DaSilva AM, Jones AM, Julien-Williams P, et al. Severity and outcome of cystic lung disease in women with tuberous sclerosis complex. Eur Respir J. 2015;45(1):171-80. https:\/\/doi.org\/10.1183\/09031936.00088314","DOI":"10.1183\/09031936.00088314"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"33.        Taveira-DaSilva AM, Hedin C, Stylianou MP, Travis WD, Matsui K, Ferrans VJ, et al. Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2001;164(6):1072-6. https:\/\/doi.org\/10.1164\/ajrccm.164.6.2102125","DOI":"10.1164\/ajrccm.164.6.2102125"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"34.        Hayashida M, Seyama K, Inoue Y, Fujimoto K, Kubo K; Respiratory Failure Research Group of the Japanese Ministry of Health, Labor, and Welfare. The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross-sectional study of presenting features and prognostic factors. Respirology. 2007;12(4):523-30. https:\/\/doi.org\/10.1111\/j.1440-1843.2007.01101.x","DOI":"10.1111\/j.1440-1843.2007.01101.x"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"35.        Hayashida M., Yasuo M., Hanaoka M. Reductions in pulmonary function detected in patients with lymphangioleiomyomatosis: an analysis of the Japanese National Research Project on Intractable Diseases database. Respir Investig. 2016;54(3):193-200. https:\/\/doi.org\/10.1016\/j.resinv.2015.11.003","DOI":"10.1016\/j.resinv.2015.11.003"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"36.        Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med. 1999;160(2):628-33. https:\/\/doi.org\/10.1164\/ajrccm.160.2.9901027","DOI":"10.1164\/ajrccm.160.2.9901027"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"37.        Xu W, Yang C, Cheng C, Wang Y, Hu D, Huang J, et al. Determinants of progression and mortality in lymphangioleiomyomatosis. Chest. 2023;164(1):136-48. https:\/\/doi.org\/10.1016\/j.chest.2023.02.026","DOI":"10.1016\/j.chest.2023.02.026"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"38.        McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595-606. https:\/\/doi.org\/10.1056\/NEJMoa1100391","DOI":"10.1056\/NEJMoa1100391"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"39.        Baldi BG, Carvalho CRR, Dias OM, Marchiori E, Hochhegger B. Diffuse cystic lung diseases: differential diagnosis. J Bras Pneumol. 2017;43(2):140-9. https:\/\/doi.org\/10.1590\/s1806-37562016000000341","DOI":"10.1590\/s1806-37562016000000341"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"40.        de Oliveira MR, Dias OM, Amaral AF, do Nascimento ECT, Wanderley M, Carvalho CRR, et al. Diffuse cystic lung disease as the primary tomographic manifestation of bronchiolitis: a case series. Pulmonology. 2020;26(6):403-6. https:\/\/doi.org\/10.1016\/j.pulmoe.2020.01.006","DOI":"10.1016\/j.pulmoe.2020.01.006"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"41.        Crivelli P, Ledda RE, Terraneo S, Conti M, Imeri G, Lesma E, et al. Role of thoracic imaging in the management of lymphangioleiomyomatosis. Respir Med. 2019;157:14-20. https:\/\/doi.org\/10.1016\/j.rmed.2019.08.013","DOI":"10.1016\/j.rmed.2019.08.013"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"42.        Wang MX, Segaran N, Bhalla S, Pickhardt PJ, Lubner MG, Katabathina VS, et al. Tuberous sclerosis: current update. Radiographics. 2021;41(7):1992-2010. https:\/\/doi.org\/10.1148\/rg.2021210103","DOI":"10.1148\/rg.2021210103"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"43.        von Ranke FM, Zanetti G, e Silva JL, Araujo Neto CA, Godoy MC, Souza CA, et al. Tuberous sclerosis complex: state-of-the-art review with a focus on pulmonary involvement. Lung. 2015;193(5):619-27. https:\/\/doi.org\/10.1007\/s00408-015-9750-6","DOI":"10.1007\/s00408-015-9750-6"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"44.        Gopalakrishnan V, Yao J, Steagall WK, Avila NA, Taveira-DaSIlva AM, Stylianou M, et al. Use of CT imaging to quantify progression and response to treatment in lymphangioleiomyomatosis. Chest. 2019;155(5):962-71. https:\/\/doi.org\/10.1016\/j.chest.2019.01.004","DOI":"10.1016\/j.chest.2019.01.004"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"45.        Baral A, Lee S, Hussaini F, Matthew B, Lebron A, Wang M, et al. Clinical trial validation of automated segmentation and scoring of pulmonary cysts in thoracic CT scans. Diagnostics (Basel). 2024;14(14). https:\/\/doi.org\/10.3390\/diagnostics14141529","DOI":"10.3390\/diagnostics14141529"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"46.        Golbus AE, Steveson C, Schuzer JL, Rollison SF, Worthy T, Jones AM, et al. Ultra-low dose chest CT with silver filter and deep learning reconstruction significantly reduces radiation dose and retains quantitative information in the investigation and monitoring of lymphangioleiomyomatosis (LAM). Eur Radiol. 2024;34(9):5613-20. https:\/\/doi.org\/10.1007\/s00330-024-10649-z","DOI":"10.1007\/s00330-024-10649-z"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"47.        Hu-Wang E, Schuzer JL, Rollison S, Leifer ES, Steveson C, Gopalakrishnan V, et al. Chest CT scan at radiation dose of a posteroanterior and lateral chest radiograph series: a proof of principle in lymphangioleiomyomatosis. Chest. 2019;155(3):528-33. https:\/\/doi.org\/10.1016\/j.chest.2018.09.007","DOI":"10.1016\/j.chest.2018.09.007"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"48.        Yao J, Taveira-DaSilva AM, Colby TV, Moss J. CT grading of lung disease in lymphangioleiomyomatosis. AJR Am J Roentgenol. 2012;199(4):787-93. https:\/\/doi.org\/10.2214\/AJR.11.7888","DOI":"10.2214\/ajr.11.7888"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"49.        Baldi BG, Araujo MS, Freitas CS, da Silva Teles GB, Kairalla RA, Dias OM, et al. Evaluation of the extent of pulmonary cysts and their association with functional variables and serum markers in lymphangioleiomyomatosis (LAM). Lung. 2014;192(6):967-74. https:\/\/doi.org\/10.1007\/s00408-014-9641-2","DOI":"10.1007\/s00408-014-9641-2"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"50.        Amaral AF, de Oliveira MR, Dias OM, Arimura FE, Freitas CSG, Acencio MMP, et al. Concentration of serum vascular endothelial growth factor (VEGF-D) and its correlation with functional and clinical parameters in patients with lymphangioleiomyomatosis from a Brazilian reference center. Lung. 2019;197(2):139-46. https:\/\/doi.org\/10.1007\/s00408-018-00191-3","DOI":"10.1007\/s00408-018-00191-3"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"51.        Hirose M, Matsumuro A, Arai T, Sugimoto C, Akira M, Kitaichi M, et al. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis. PLoS One. 2019;14(2):1-15. https:\/\/doi.org\/10.1371\/journal.pone.0212776","DOI":"10.1371\/journal.pone.0212776"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"52.        Amaral AF, Carvalho CRR, Baldi BG. Something not so new for lymphangioleiomyomatosis: is VEGF-D a glass half empty or half full? J Bras Pneumol. 2022;48(1): e20220046. https:\/\/doi.org\/10.36416\/1806-3756\/e20220046","DOI":"10.36416\/1806-3756\/e20220046"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"53.        Li M, Zhu WY, Wang J, Yang XD, Li WM, Wang G. Diagnostic performance of VEGF-D for lymphangioleiomyomatosis: a meta-analysis. J Bras Pneumol. 2022;48(1):e20210337. https:\/\/doi.org\/10.36416\/1806-3756\/e20210337","DOI":"10.36416\/1806-3756\/e20210337"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"54.        Koba T, Arai T, Kitaichi M, Kasai T, Hirose M, Tachibana K, et al. Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: a report of 24 consecutive patients. Respirology. 2018;23(3):331-8. https:\/\/doi.org\/10.1111\/resp.13190","DOI":"10.1111\/resp.13190"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"55.        Xu W, Cui H, Liu H, Feng R, Tian X, Yang Y, et al. The value of transbronchial lung biopsy in the diagnosis of lymphangioleiomyomatosis. BMC Pulm Med. 2021;21(1):146. https:\/\/doi.org\/10.1186\/s12890-021-01518-2","DOI":"10.1186\/s12890-021-01518-2"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"56.        Yao Y, Chen X, Chen H, Xiao Z, Li S. Safety and efficacy of cryobiopsy for the diagnosis of lymphangioleiomyomatosis compared with forceps biopsy and surgical lung biopsy. BMC Pulm Med. 2023;23(1):510. https:\/\/doi.org\/10.1186\/s12890-023-02810-z","DOI":"10.1186\/s12890-023-02810-z"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"57.        Yoshida M, Awano N, Inomata M, Kuse N, Tone M, Yoshimura H, et al. Diagnostic usefulness of transbronchial lung cryobiopsy in two patients mildly affected with pulmonar lymphangioleiomyomatosis. Respir Invest. 2020;58(4):295-9. https:\/\/doi.org\/10.1016\/j.resinv.2020.02.005","DOI":"10.1016\/j.resinv.2020.02.005"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"58.        Kumasaka T, Seyama K, Mitani K, Sato T, Souma S, Kondo T, et al. Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis. Am J Surg Pathol. 2004;28(8):1007-16. https:\/\/doi.org\/10.1097\/01.pas.0000126859.70814.6d","DOI":"10.1097\/01.pas.0000126859.70814.6d"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"59.        Martignoni G, Pea M, Reghellin D, Zamboni G, Bonetti F. PEComas: the past, the present and the future. Virchows Arch. 2008;452(2):119-32. https:\/\/doi.org\/10.1007\/s00428-007-0509-1","DOI":"10.1007\/s00428-007-0509-1"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"60.        Glassberg MK, Elliot SJ, Fritz J, Catanuto P, Portier M, Donahue R, et al. Activation of the estrogen receptor contributes to the progression of pulmonary lymphangioleiomyomatosis via matrix metalloproteinase-induced cell invasiveness. J Clin Endocrinol Metab. 2008;93(5):1625-33. https:\/\/doi.org\/10.1210\/jc.2007-1283","DOI":"10.1210\/jc.2007-1283"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"61.        Goncharova EA, Krymskaya VP. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges. J Cell Biochem. 2008;103(2):369-82. https:\/\/doi.org\/10.1002\/jcb.21419","DOI":"10.1002\/jcb.21419"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"62.        Krymskaya VP. Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis. Proc Am Thorac Soc. 2008;5(1):119-26. https:\/\/doi.org\/10.1513\/pats.200705-061VS","DOI":"10.1513\/pats.200705-061VS"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"63.        Juvet SC, McCormack FX, Kwiatkowski DJ, Downey GP. Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol. 2007;36(4):398-408. https:\/\/doi.org\/10.1165\/rcmb.2006-0372TR","DOI":"10.1165\/rcmb.2006-0372tr"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"64.        Nascimento ECTD, Baldi BG, Mariani AW, Annoni R, Kairalla RA, Pimenta SP, et al. Immunohistological features related to functional impairment in lymphangioleiomyomatosis. Respir Res. 2018;19(1):83. https:\/\/doi.org\/10.1186\/s12931-018-0797-9","DOI":"10.1186\/s12931-018-0797-9"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"65.        Bonetti F, Chiodera PL, Pea M, Martignoni G, Bosi F, Zamboni G, et al. Transbronchial biopsy in lymphangioleiomyomatosis of the lung. HMB-45 for diagnosis. Am J Surg Pathol. 1993;17(11):1092-102. https:\/\/doi.org\/10.1097\/00000478-199311000-00002","DOI":"10.1097\/00000478-199311000-00002"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"66.        Rolim I, Makupson M, Lovrenski A, Farver C. Cathepsin K is superior to HMB45 for the diagnosis of pulmonary lymphangioleiomyomatosis. Appl Immunohistochem Mol Morphol. 2022;30(2):108-12. https:\/\/doi.org\/10.1097\/PAI.0000000000000968","DOI":"10.1097\/pai.0000000000000968"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"67.        Flavin RJ, Cook J, Fiorentino M, Bailey D, Brown M, Loda MF. \u03b2-Catenin is a useful adjunct immunohistochemical marker for the diagnosis of pulmonary lymphangioleiomyomatosis. Am J Clin Pathol. 2011;135(5):776-82. https:\/\/doi.org\/10.1309\/AJCPPC9EX1ZHMRMA","DOI":"10.1309\/ajcppc9ex1zhmrma"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"68.        Xu KF, Xu W, Liu S, Yu J, Tian X, Yang Y, et al. Lymphangioleiomyomatosis. Semin Respir Crit Care Med. 2020;41(2):256-68. https:\/\/doi.org\/10.1055\/s-0040-1702195","DOI":"10.1055\/s-0040-1702195"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"69.        Krymskaya VP. Tumor suppressors hamartin and tuberin: intracellular signalling. Cell Signal. 2003;15(8):729-39. https:\/\/doi.org\/10.1016\/S0898-6568(03)00040-8","DOI":"10.1016\/s0898-6568(03)00040-8"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"70.        Hohman DW, Noghrehkar D, Ratnayake S. Lymphangioleiomyomatosis: a review. Eur J Intern Med. 2008;19(5):319-24. https:\/\/doi.org\/10.1016\/j.ejim.2007.10.015","DOI":"10.1016\/j.ejim.2007.10.015"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"71.        Taveira Da-Silva AM, Steagall WK, Moss J. Lymphangioleiomyomatosis. Cancer Control. 2006;13(4):276-85. https:\/\/doi.org\/10.1177\/107327480601300405","DOI":"10.1177\/107327480601300405"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"72.        Burgstaller S, Rosner M, Lindengr\u00fcn C, Hanneder M, Siegel N, Valli A, et al. Tuberin, p27 and mTOR in different cells. Amino Acids. 2009;36(2):297-302. https:\/\/doi.org\/10.1007\/s00726-008-0066-1","DOI":"10.1007\/s00726-008-0066-1"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"73.        Lesma E, Grande V, Carelli S, Brancaccio D, Canevini MP, Alfano RM, et al. Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma: epidermal growth factor is the required growth factor. Am J Pathol. 2005;167(4):1093-103. https:\/\/doi.org\/10.1016\/S0002-9440(10)61198-4","DOI":"10.1016\/s0002-9440(10)61198-4"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"74.        Robb VA, Astrinidis A, Henske EP. Frequent hyperphosphorylation of ribosomal protein S6 in lymphangioleiomyomatosis-associated angiomyolipomas. Mod Pathol. 2006;19(6):839-46. https:\/\/doi.org\/10.1038\/modpathol.3800610","DOI":"10.1038\/modpathol.3800610"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"75.        McCormack FX. Lymphangioleiomyomatosis: a clinical update. Chest. 2008;133(2):507-16. https:\/\/doi.org\/10.1378\/chest.07-0898","DOI":"10.1378\/chest.07-0898"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"76.        Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Kristof AS, Avila NA, Rabel A, et al. Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2003;168(12):1427-31. https:\/\/doi.org\/10.1164\/rccm.200206-593OC","DOI":"10.1164\/rccm.200206-593oc"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"77.        Araujo MS, Baldi BG, Freitas CS, Albuquerque AL, Marques da Silva CC, Kairalla RA, et al. Pulmonary rehabilitation in lymphangioleiomyomatosis: a controlled clinical trial. Eur Respir J. 2016;47(5):1452-60. https:\/\/doi.org\/10.1183\/13993003.01683-2015","DOI":"10.1183\/13993003.01683-2015"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"78.        Queiroz DS, da Silva CCBM, Amaral AF, Oliveira MR, Moriya HT, Carvalho CRR, et al. Desaturation-distance ratio during submaximal and maximal exercise tests and its association with lung function parameters in patients with lymphangioleiomyomatosis. Front Med (Lausanne). 2021;8:659416. https:\/\/doi.org\/10.3389\/fmed.2021.659416","DOI":"10.3389\/fmed.2021.659416"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"79.        Freitas CSG, Baldi BG, Jardim C, Araujo MS, Sobral JB, Heiden GI, et al. Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method. Orphanet J Rare Dis. 2017;12(1):74. https:\/\/doi.org\/10.1186\/s13023-017-0626-0","DOI":"10.1186\/s13023-017-0626-0"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"80.        Strom JA. Have noninvasive imaging studies supplanted the need for invasive hemodynamics: lessons learned from lymphangioleiomyomatosis. J Am Soc Echocardiogr. 2018;31(8):902-4. https:\/\/doi.org\/10.1016\/j.echo.2018.06.003","DOI":"10.1016\/j.echo.2018.06.003"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"81.        Taveira-DaSilva AM, Hathaway OM, Sachdev V, Shizukuda Y, Birdsall CM, Moss J. Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study. Chest 2007;132(5):1573-8. https:\/\/doi.org\/10.1378\/chest.07-1205","DOI":"10.1378\/chest.07-1205"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"82.        Shlobin OA, Adir Y, Barbera JA, Cottin V, Harari S, Jutant EM, et al. Pulmonary hypertension associated with lung diseases. Eur Respir J. 2024 64(4):2401200.. https:\/\/doi.org\/10.1183\/13993003.01200-2024","DOI":"10.1183\/13993003.01200-2024"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"83.        Baldi BG, Fernandes CJCS, Heiden GI, Freitas CSG, Sobral JB, Kairalla RA, et al. Association between pulmonary artery to aorta diameter ratio with pulmonary hypertension and outcomes in diffuse cystic lung diseases. Medicine (Baltimore). 2021;100(25):e26483. https:\/\/doi.org\/10.1097\/MD.0000000000026483","DOI":"10.1097\/md.0000000000026483"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"84.        Sonaglioni A, Baravelli M, Cassandro R, Torre O, Elia D, Anz\u00e0 C, et al. Hemodynamic mechanisms of exercise-induced pulmonary hypertension in patients with lymphangioleiomyomatosis: the role of exercise stress echocardiography. J Am Soc Echocardiogr. 2018;31(8):888-901. https:\/\/doi.org\/10.1016\/j.echo.2018.02.004","DOI":"10.1016\/j.echo.2018.02.004"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"85.        Young LR, Lee HS, Inoue Y, Moss J, Singer LG, Strange C, et al. Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med. 2013;1(6):445-52. https:\/\/doi.org\/10.1016\/S2213-2600(13)70090-0","DOI":"10.1016\/s2213-2600(13)70090-0"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"86.        Ando K, Kurihara M, Kataoka H, Ueyama M, Togo S, Sato T, et al. The efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis. Respir Investig. 2013;51(3):174-83. https:\/\/doi.org\/10.1016\/j.resinv.2013.03.002","DOI":"10.1016\/j.resinv.2013.03.002"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"87.        Harari S, Torre O, Elia D, Caminati A, Pelosi G, Specchia C, et al. Improving survival in lymphangioleiomyomatosis: a 16-year observational study in a large cohort of patients. Respiration. 2021;100:989-99. https:\/\/doi.org\/10.1159\/000516330","DOI":"10.1159\/000516330"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"88.        Taveira-DaSilva AM, Julien-Williams P, Jones AM, Stylianou M, Moss J. Rates of change of FEV1 and DLCO as potential indicators for mTOR inhibitor therapy in premenopausal lymphangioleiomyomatosis patients. Eur Respir J. 2018;51(4):1702258. https:\/\/doi.org\/10.1183\/13993003.02258-2017","DOI":"10.1183\/13993003.02258-2017"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"89.        Yoon HY, Hwang JJ, Kim DS, Song JW. Efficacy and safety of low-dose sirolimus in lymphangioleiomyomatosis. Orphanet J Rare Dis. 2018;13(1):204. https:\/\/doi.org\/10.1186\/s13023-018-0946-8","DOI":"10.1186\/s13023-018-0946-8"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"90.        Cheng C, Xu W, Wang Y, Zhang T, Yang L, Zhou W, et al. Sirolimus reduces the risk of pneumothorax recurrence in patients with lymphangioleiomyomatosis: a historical prospective self-controlled study. Orphanet J Rare Dis. 2022;17(1):257. https:\/\/doi.org\/10.1186\/s13023-022-02418-2","DOI":"10.1186\/s13023-022-02418-2"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"91.        Sakurai T, Arai T, Hirose M, Kojima K, Sakamoto T, Matsuda Y, et al. Reduced risk of recurrent pneumothorax for sirolimus therapy after surgical pleural covering of entire lung in lymphangioleiomyomatosis. Orphanet J Rare Dis. 2021;16(1):466. https:\/\/doi.org\/10.1186\/s13023-021-02081-z","DOI":"10.1186\/s13023-021-02081-z"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"92.        Takada T, Mikami A, Kitamura N, Seyama K, Inoue Y, Nagai K, et al. Efficacy and safety of long-term sirolimus therapy for Asian patients with lymphangioleiomyomatosis. Ann Am Thorac Soc. 2016;13(11):1912-22. https:\/\/doi.org\/10.1513\/AnnalsATS.201605-335OC","DOI":"10.1513\/annalsats.201605-335oc"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"93.        Hu S, Wu X, Wu W, Tian X, Yang Y, Wang ST, et al. Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis. Orphanet J Rare Dis. 2019;14(1):206. https:\/\/doi.org\/10.1186\/s13023-019-1178-2","DOI":"10.1186\/s13023-019-1178-2"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"94.        Taveira-DaSilva AM, Jones AM, Julien-Williams P, Stylianou M, Moss J. Long-term effect of sirolimus on serum vascular endothelial growth factor D levels in patients with lymphangioleiomyomatosis. Chest. 2018;153(1):124-32. https:\/\/doi.org\/10.1016\/j.chest.2017.05.012","DOI":"10.1016\/j.chest.2017.05.012"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"95.        Goldberg HJ, Harari S, Cottin V, Rosas IO, Peters E, Biswal S, et al. Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. Eur Respir J. 2015;46(3):783-94. https:\/\/doi.org\/10.1183\/09031936.00210714","DOI":"10.1183\/09031936.00210714"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"96.        Taveira-Dasilva AM, Steagall WK, Rabel A, Hathaway O, Harari S, Cassandro R, et al. Reversible airflow obstruction in lymphangioleiomyomatosis. Chest. 2009;136(6):1596-1603. https:\/\/doi.org\/10.1378\/chest.09-0624","DOI":"10.1378\/chest.09-0624"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"97.        Baldi BG, de Albuquerque AL, Pimenta SP, Salge JM, Kairalla RA, Carvalho CR. A pilot study assessing the effect of bronchodilator on dynamic hyperinflation in LAM. Respir Med. 2013;107(11):1773-80. https:\/\/doi.org\/10.1016\/j.rmed.2013.08.045","DOI":"10.1016\/j.rmed.2013.08.045"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"98.        Johnson J, Johnson SR. Cross-sectional study of reversible airway obstruction in LAM: better evidence is needed for bronchodilator and inhaled steroid use. Thorax. 2019;74(10):999-1002. https:\/\/doi.org\/10.1136\/thoraxjnl-2019-213338","DOI":"10.1136\/thoraxjnl-2019-213338"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"99.        Moir LM. Lymphangioleiomyomatosis: current understanding and potential treatments. Pharmacol Ther. 2016;158:114-24. https:\/\/doi.org\/10.1016\/j.pharmthera.2015.12.008","DOI":"10.1016\/j.pharmthera.2015.12.008"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"100.     Johnson SR, Whale CI, Hubbard RB, Lewis SA, Tattersfield AE. Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax. 2004;59(9):800-3. https:\/\/doi.org\/10.1136\/thx.2004.023283","DOI":"10.1136\/thx.2004.023283"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"101.     Almoosa KF, Ryu JH, Mendez J, Huggins JT, Young LR, Sullivan EJ, et al. Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications. Chest. 2006;129(5):1274-81. https:\/\/doi.org\/10.1378\/chest.129.5.1274","DOI":"10.1378\/chest.129.5.1274"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"102.     Gonano C, Pasquier J, Daccord C, Johnson SR, Harari S, Leclerc V, et al. Air travel and incidence of pneumothorax in lymphangioleiomyomatosis. Orphanet J Rare Dis. 2018;13(1):222. https:\/\/doi.org\/10.1186\/s13023-018-0964-6","DOI":"10.1186\/s13023-018-0964-6"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"103.     Suzuki E, Kurihara M, Tsuboshima K, Watanabe K, Okamoto S, Seyama K. The effects of total pleural covering on pneumothorax recurrence and pulmonary function in lymphangioleiomyomatosis patients without history of pleurodesis or thoracic surgeries for pneumothorax. J Thorac Dis. 2021;13(1):113-24. https:\/\/doi.org\/10.21037\/jtd-20-2286","DOI":"10.21037\/jtd-20-2286"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"104.     Zhou L, Ouyang R, Luo H, Ren S, Chen P, Peng Y, et al. Efficacy of sirolimus for the prevention of recurrent pneumothorax in patients with lymphangioleiomyomatosis: a case series. Orphanet J Rare Dis. 2018;13(1):168. https:\/\/doi.org\/10.1186\/s13023-018-0915-2","DOI":"10.1186\/s13023-018-0915-2"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"105.     Lama A, Ferreiro L, Golpe A, Gude F, \u00c1lvarez-Doba\u00f1o JM, Gonz\u00e1lez-Barcala FJ, et al. Characteristics of patients with lymphangioleiomyomatosis and pleural effusion: a systematic review. Respiration. 2016;91(3):256-64. https:\/\/doi.org\/10.1159\/000444264","DOI":"10.1159\/000444264"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"106.     Ryu JH, Doerr CH, Fisher SD, Olson EJ, Sahn SA. Chylothorax in lymphangioleiomyomatosis. Chest. 2003;123(2):623-7. https:\/\/doi.org\/10.1378\/chest.123.2.623","DOI":"10.1378\/chest.123.2.623"},{"key":"ref107","doi-asserted-by":"publisher","unstructured":"107.     Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med. 2011;154(12):797-805. https:\/\/doi.org\/10.7326\/0003-4819-154-12-201106210-00007","DOI":"10.7326\/0003-4819-154-12-201106210-00007"},{"key":"ref108","doi-asserted-by":"publisher","unstructured":"108.     Karagianis J, Sheean PM. Managing secondary chylothorax: the implications for medical nutrition therapy. J Am Diet Assoc. 2011;111(4):600-4. https:\/\/doi.org\/10.1016\/j.jada.2011.01.014","DOI":"10.1016\/j.jada.2011.01.014"},{"key":"ref109","unstructured":"109.     Cirilo MAS, Nascimento CX, Sousa BS. Enteral diet supply in medium chain triglycerid as a therapeutic coadjuvant in a case of bilateral chylothorax secondary to follicular lymphoma [Article in Portuguese]. Nutri Clin Diet Hosp. 2018;38(1):170-174. https:\/\/doi.org\/0.12873\/381BSoares"},{"key":"ref110","doi-asserted-by":"publisher","unstructured":"110.     Stanifer BP, Harris S, Nguyen SN, Vinogradsky AV, Trivedi N, Fonseca L, et al. Surgical management of pleural complications in lymphangioleiomyomatosis. J Thorac Cardiovasc Surg. 2024:S0022-5223(24)00772-4. https:\/\/doi.org\/10.1016\/j.jtcvs.2024.08.038","DOI":"10.1016\/j.jtcvs.2024.08.038"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"111.     Schmid BP, Gilberto GM, Cunha MJS, Valle LGM, Foronda G, Arrieta SR, et al. The essential role of thoracic duct embolization in management of traumatic iatrogenic chylothorax. J Vasc Bras. 2023;22:e20230101. https:\/\/doi.org\/10.1590\/1677-5449.20230101","DOI":"10.1590\/1677-5449.20230101"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"112.     Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817-24. https:\/\/doi.org\/10.1016\/S0140-6736(12)61767-X","DOI":"10.1016\/s0140-6736(12)61767-x"},{"key":"ref113","doi-asserted-by":"publisher","unstructured":"113.     Mekahli D, Muller RU, Marlais M, Wlodkowski T, Haeberle S, Argumedo ML, et al. Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & KidneyWorking Group. Nat Rev Nephrol 2024;20(6):402-20. https:\/\/doi.org\/10.1038\/s41581-024-00818-0","DOI":"10.1038\/s41581-024-00818-0"},{"key":"ref114","doi-asserted-by":"publisher","unstructured":"114.     Khaddam S, Gulati S. Spectrum of presentations and management strategies in renal angiomyolipoma. J Kidney Cancer VHL. 2022;9(1):42-7. https:\/\/doi.org\/10.15586\/jkcvhl.v9i1.221","DOI":"10.15586\/jkcvhl.v9i1.221"},{"key":"ref115","doi-asserted-by":"publisher","unstructured":"115.     Toei H, Zhang X, Seyama K, Yashiro D, Kuwatsuru Y, Kuwatsuru R. Prophylactic renal artery embolization before pregnancy in patients with lymphangioleiomyomatosis and renal angiomyolipoma. J Int Med Res. 2022; 50(9):1-12. https:\/\/doi.org\/10.1177\/03000605221123897","DOI":"10.1177\/03000605221123897"},{"key":"ref116","doi-asserted-by":"publisher","unstructured":"116.     Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358(2):140-51. https:\/\/doi.org\/10.1056\/NEJMoa063564","DOI":"10.2215\/01.cjn.0000927000.05849.4d"},{"key":"ref117","doi-asserted-by":"publisher","unstructured":"117.     Cabrera-Lo\u0301pez C, Marti T, Catal\u00e1 V, Torres F, Mateu S, Ballarin J, et al. Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial. Orphanet J Rare Dis. 2012;7(87):1-9. https:\/\/doi.org\/10.1186\/1750-1172-7-87","DOI":"10.1186\/1750-1172-7-87"},{"key":"ref118","doi-asserted-by":"publisher","unstructured":"118.     Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011;17(12):4071-81. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0445","DOI":"10.1158\/1078-0432.ccr-11-0445"},{"key":"ref119","doi-asserted-by":"publisher","unstructured":"119.     Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol Dial Transplant. 2016;31:111-9. https:\/\/doi.org\/10.1093\/ndt\/gfv249","DOI":"10.1093\/ndt\/gfv249"},{"key":"ref120","doi-asserted-by":"publisher","unstructured":"120.     Bissler JJ, Budde K, Sauter M, Franz DN, Zonnenberg BA, Frost MD, et al. Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. Nephrol Dial Transplant. 2019;34(6):1000-8. https:\/\/doi.org\/10.1093\/ndt\/gfy132","DOI":"10.1093\/ndt\/gfy132"},{"key":"ref121","doi-asserted-by":"publisher","unstructured":"121.     Hatano T, Inaba H, Endo K, Egawa S. Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complex. Int J Urol. 2017;24(11):780-5. https:\/\/doi.org\/10.1111\/iju.13428","DOI":"10.1111\/iju.13428"},{"key":"ref122","doi-asserted-by":"publisher","unstructured":"122.     Mohammadieh AM, Bowler SD, Yates DH. Everolimus treatment of abdominal lymphangioleiomyoma in five women with sporadic lymphangioleiomyomatosis. MJA. 2013;199(2):121-3. https:\/\/doi.org\/10.5694\/mja12.11567","DOI":"10.5694\/mja12.11567"},{"key":"ref123","doi-asserted-by":"publisher","unstructured":"123.     Hirose K, Isimaru Y, Sakata S, Sakagami T. Rapid shrinkage of retroperitoneal lymphangioleiomyoma after sirolimus initiation. Intern Med. 2022;61(13):2081-2. https:\/\/doi.org\/10.2169\/internalmedicine.8685-21","DOI":"10.2169\/internalmedicine.8685-21"},{"key":"ref124","doi-asserted-by":"publisher","unstructured":"124.     Gloeckl R, Nell C, Schneeberger T, Jarosch I, Boensch M, Watz H, et al. Benefits of pulmonary rehabilitation in patients with advanced lymphangioleiomyomatosis (LAM) compared with COPD - a retrospective analysis. Orphanet J Rare Dis. 2020;15(1):255. https:\/\/doi.org\/10.1186\/s13023-020-01540-3","DOI":"10.1186\/s13023-020-01540-3"},{"key":"ref125","doi-asserted-by":"publisher","unstructured":"125.     Child CE, Kelly ML, Sizelove H, Garvin M, Guilliams J, Kim P, et al. A remote monitoring-enabled home exercise prescription for patients with interstitial lung disease at risk for exercise-induced desaturation. Respir Med. 2023;218:107397. https:\/\/doi.org\/10.1016\/j.rmed.2023.107397","DOI":"10.1016\/j.rmed.2023.107397"},{"key":"ref126","doi-asserted-by":"crossref","unstructured":"126.     Li X, Xu W, Zhang L, Zu Y, Li Y, Yang Y, et al. Effects of yoga on exercise capacity in patients with lymphangioleiomyomatosis: a nonrandomized controlled study. Orphanet J Rare Dis. 2020;15(1):72. https:\/\/doi.org\/10.1186\/s13023-020-1344-6","DOI":"10.1186\/s13023-020-1344-6"},{"key":"ref127","doi-asserted-by":"publisher","unstructured":"127.     Child CE, Ho LA, Lachant D, Gupta N, Moss J, Jones A, et al. Unsupervised exercise in interstitial lung disease: a Delphi study to develop a consensus preparticipation screening tool for lymphangioleiomyomatosis. Chest. 2024;166(5):1108-1123. https:\/\/doi.org\/10.1016\/j.chest.2024.06.3803","DOI":"10.1016\/j.chest.2024.06.3803"},{"key":"ref128","doi-asserted-by":"publisher","unstructured":"128.     Medeiros VMG, Gon\u00e7alves de Lima J, Rosa C, Rega J, Mediano MFF, Rodrigues Junior LF. Physiotherapy in lymphangioleiomyomatosis: a systematic review. Ann Med. 2022;54(1):2744-51. https:\/\/doi.org\/10.1080\/07853890.2022.2128401","DOI":"10.1080\/07853890.2022.2128401"},{"key":"ref129","doi-asserted-by":"publisher","unstructured":"129.     Clemm C, Jehn U, Wolf-Hornung B, Siemon G, Walter G. Lymphangiomyomatosis: a report of three cases treated with tamoxifen. Klin Wochenschr. 1987;65(8):391-3. https:\/\/doi.org\/10.1007\/BF01745582","DOI":"10.1007\/bf01745582"},{"key":"ref130","doi-asserted-by":"publisher","unstructured":"130.     Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest. 2004;126(6):1867-74. https:\/\/doi.org\/10.1378\/chest.126.6.1867","DOI":"10.1378\/chest.126.6.1867"},{"key":"ref131","doi-asserted-by":"publisher","unstructured":"131.     Harari S, Cassandro R, Chiodini I, Taveira-DaSilva AM, Moss J. Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis. Chest. 2008;133(2):448-54. https:\/\/doi.org\/10.1378\/chest.07-2277","DOI":"10.1378\/chest.07-2277"},{"key":"ref132","doi-asserted-by":"publisher","unstructured":"132.     Baldi BG, Medeiros Junior P, Pimenta SP, Lopes RI, Kairalla RA, Carvalho CR. Evolution of pulmonary function after treatment with goserelin in patients with lymphangioleiomyomatosis. J Bras Pneumol. 2011;37(3):375-9. https:\/\/doi.org\/10.1590\/S1806-37132011000300015","DOI":"10.1590\/s1806-37132011000300015"},{"key":"ref133","doi-asserted-by":"publisher","unstructured":"133.     Lu C, Lee HS, Pappas GP, Dilling DF, Burger CD, Shifren A, et al. A phase II clinical trial of an aromatase inhibitor for postmenopausal women with lymphangioleiomyomatosis. Ann Am Thorac Soc. 2017;14(6):919-28. https:\/\/doi.org\/10.1513\/AnnalsATS.201610-824OC","DOI":"10.1513\/annalsats.201610-824oc"},{"key":"ref134","doi-asserted-by":"publisher","unstructured":"134.     Castellano MVCO, Pereira LFF, Feitosa PHR, Knorst MM, Salim C, Rodrigues MM, et al. 2022 Brazilian Thoracic Association recommendations for long-term home oxygen therapy. J Bras Pneumol. 2022;48(5):e20220179. https:\/\/doi.org\/10.36416\/1806-3756\/e20220179","DOI":"10.36416\/1806-3756\/e20220179"},{"key":"ref135","doi-asserted-by":"publisher","unstructured":"135.     Jacobs SS, Krishnan JA, Lederer DJ, Ghazipura M, Hossain T, Tan AM, et al. Home oxygen therapy for adults with chronic lung disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(10):e121-e141. https:\/\/doi.org\/10.1164\/rccm.202009-3608ST","DOI":"10.1164\/rccm.202009-3608st"},{"key":"ref136","doi-asserted-by":"publisher","unstructured":"136.     Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014 - an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34(1):1-15. https:\/\/doi.org\/10.1016\/j.healun.2014.06.014","DOI":"10.1016\/j.healun.2014.06.014"},{"key":"ref137","doi-asserted-by":"publisher","unstructured":"137.     Warrior K, Dilling DF. Lung transplantation for lymphangioleiomyomatosis. J Heart Lung Transplant. 2023;42(1):40-52. https:\/\/doi.org\/10.1016\/j.healun.2022.09.021","DOI":"10.1016\/j.healun.2022.09.021"},{"key":"ref138","doi-asserted-by":"publisher","unstructured":"138.     Baldi BG, Samano MN, Campos SV, Oliveira MR, Junior JEA, Carraro RM, et al. Experience of lung transplantation in patients with lymphangioleiomyomatosis at a Brazilian reference centre. Lung. 2017;195(6):699-705. https:\/\/doi.org\/10.1007\/s00408-017-0045-y","DOI":"10.1007\/s00408-017-0045-y"},{"key":"ref139","doi-asserted-by":"publisher","unstructured":"139.     Khawar MU, Yazdani D, Zhu Z, Jandarov R, Dilling DF, Gupta N. Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis. J Heart Lung Transplant. 2019;38(9):949-55. https:\/\/doi.org\/10.1016\/j.healun.2019.06.015","DOI":"10.1016\/j.healun.2019.06.015"},{"key":"ref140","doi-asserted-by":"publisher","unstructured":"140.     Benden C, Rea F, Behr J, Corris PA, Reynaud-Gaubert M, Stern M, et al. Lung transplantation for lymphangioleiomyomatosis: the European experience. J Heart Lung Transplant. 2009;28(1):1-7. https:\/\/doi.org\/10.1016\/j.healun.2008.09.014","DOI":"10.1016\/j.healun.2008.09.014"},{"key":"ref141","doi-asserted-by":"publisher","unstructured":"141.     Ando K, Okada Y, Akiba M, Kondo T, Kawamura T, Okumura M, et al. Lung transplantation for lymphangioleiomyomatosis in Japan. PLoS One. 2016;11(1):e0146749. https:\/\/doi.org\/10.1371\/journal.pone.0146749","DOI":"10.1371\/journal.pone.0146749"},{"key":"ref142","doi-asserted-by":"publisher","unstructured":"142.     Zhang J, Liu D, Yue B, Ban L, Zhou M, Wang H, et al. A retrospective study of lung transplantation in patients with lymphangioleiomyomatosis: challenges and outcomes. Front Med. 2021;8:584826. https:\/\/doi.org\/10.3389\/fmed.2021.584826","DOI":"10.3389\/fmed.2021.584826"},{"key":"ref143","doi-asserted-by":"publisher","unstructured":"143.     Bittmann I, Rolf B, Amann G, L\u00f6hrs U. Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. Hum Pathol. 2003;34(1):95-8. https:\/\/doi.org\/10.1053\/hupa.2003.50","DOI":"10.1053\/hupa.2003.50"},{"key":"ref144","doi-asserted-by":"publisher","unstructured":"144.     Sakurai T, Kanou T, Funaki S, Fukui E, Kimura T, Ose N, et al. Effect of mTOR inhibitors on the mortality and safety of patients with lymphangioleiomyomatosis on the lung transplantation waitlist: a retrospective cohort study. Respir Investig. 2024;62(4):657-62. https:\/\/doi.org\/10.1016\/j.resinv.2024.05.008","DOI":"10.1016\/j.resinv.2024.05.008"},{"key":"ref145","doi-asserted-by":"publisher","unstructured":"145.     Warrior K, Leard LE, Nair AR, Gries CJ, Fisher AJ, Johnson SR, et al. A survey of use of mTOR inhibitors in patients with lymphangioleiomyomatosis listed for lung transplant. Respir Med. 2022;195:106779. https:\/\/doi.org\/10.1016\/j.rmed.2022.106779","DOI":"10.1016\/j.rmed.2022.106779"},{"key":"ref146","doi-asserted-by":"publisher","unstructured":"146.     El-Chemaly S, Goldberg HJ, Glanville AR. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation? Expert Rev Respir Med. 2014;8(6):657-60. https:\/\/doi.org\/10.1586\/17476348.2014.956728","DOI":"10.1586\/17476348.2014.956728"},{"key":"ref147","doi-asserted-by":"publisher","unstructured":"147.     Worthy T, Jones A, Yang BE, Ishiwata-Endo H, Gupta N, Moss J. Effects of Sirolimus on anti-SARS-CoV-2 vaccination in patients with lymphangioleiomyomatosis. Chest. 2024;165(2):303-6. https:\/\/doi.org\/10.1016\/j.chest.2023.09.014","DOI":"10.1016\/j.chest.2023.09.014"},{"key":"ref148","doi-asserted-by":"publisher","unstructured":"148.     Cottrell JJ. Altitude exposures during aircraft flight. Flying higher. Chest. 1988;93(1):81-4. https:\/\/doi.org\/10.1378\/chest.93.1.81","DOI":"10.1378\/chest.93.1.81"},{"key":"ref149","doi-asserted-by":"publisher","unstructured":"149.     Cortinas N, Liu J, Kopras E, Menon H, Burkes R, Gupta N. Impact of age, menopause and sirolimus on spontaneous pneumothoraces in lymphangioleiomyomatosis. Chest. 2022;162(6):1324-7. https:\/\/doi.org\/10.1016\/j.chest.2022.05.036","DOI":"10.1016\/j.chest.2022.05.036"},{"key":"ref150","doi-asserted-by":"publisher","unstructured":"150.     Pollock-BarZiv S, Cohen MM, Downey GP, Johnson SR, Sullivan E, McCormackFX. Air travel in women with lymphangioleiomyomatosis. Thorax. 2007;62(2):176-80. https:\/\/doi.org\/10.1136\/thx.2006.058537","DOI":"10.1136\/thx.2006.058537"},{"key":"ref151","doi-asserted-by":"publisher","unstructured":"151.     Taveira-DaSilva AM, Burstein D, Hathaway OM, Fontana JR, Gochuico BR, Avila NA, et al. Pneumothorax after air travel in lymphangioleiomyomatosis, idiopathic pulmonary fibrosis, and sarcoidosis. Chest. 2009;136(3):665-70. https:\/\/doi.org\/10.1378\/chest.08-3034","DOI":"10.1378\/chest.08-3034"},{"key":"ref152","doi-asserted-by":"publisher","unstructured":"152.     Bellinghausen AL, Mandel J. Assessing patients for air travel. Chest. 2021;159(5):1961-7. https:\/\/doi.org\/10.1016\/j.chest.2020.11.002","DOI":"10.1016\/j.chest.2020.11.002"},{"key":"ref153","unstructured":"153.     Gong H Jr, Tashkin DP, Lee EY, Simmons MS. Hypoxia-altitude simulation test. Evaluation of patients with chronic airway obstruction. Am Rev Respir Dis. 1984;130(6):980-6."},{"key":"ref154","doi-asserted-by":"publisher","unstructured":"154.     Sponholz Ara\u00fajo J. Viagens a\u00e9reas em portadores de doen\u00e7a pulmonar avan\u00e7ada. In: Augusto V. Manual de Assist\u00eancia Domiciliar em Doen\u00e7a Pulmonar Avan\u00e7ada. S\u00e3o Paulo: Grupo Editorial Nacional; 2013. p. 246-65.","DOI":"10.14393\/ufu.di.2020.3308"},{"key":"ref155","doi-asserted-by":"crossref","unstructured":"155.     Drake TM, Docherty AB, Harrison EM, Quint JK, Adamali H, Agnew S, et al. Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An International Multicenter Study. Am J Respir Crit Care Med. 2020;202(12):1656-65. https:\/\/doi.org\/10.1164\/rccm.202007-2794OC","DOI":"10.1164\/rccm.202007-2794OC"},{"key":"ref156","doi-asserted-by":"publisher","unstructured":"156.     Gallay L, Uzunhan Y, Borie R, Lazor R, Rigaud P, Marchand-Adam S, et al. Risk factors for mortality after COVID-19 in patients with preexisting interstitial lung disease. Am J Respir Crit Care Med. 2021;203(2):245-9. https:\/\/doi.org\/10.1164\/rccm.202007-2638LE","DOI":"10.1164\/rccm.202007-2638le"},{"key":"ref157","doi-asserted-by":"publisher","unstructured":"157.     Baldi BG, Radzikowska E, Cottin V, Dilling DF, Ataya A, Carvalho CRR, et al. COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mechanistic target of rapamycin inhibition. Chest. 2022;161(6):1589-93. https:\/\/doi.org\/10.1016\/j.chest.2021.12.640","DOI":"10.1016\/j.chest.2021.12.640"},{"key":"ref158","doi-asserted-by":"crossref","unstructured":"158.     Cohen MM, Freyer AM, Johnson SR. Pregnancy experiences among women with lymphangioleiomyomatosis. Respir Med. 2009;103(5):766-72. https:\/\/doi.org\/10.1016\/j.rmed.2008.11.007","DOI":"10.1016\/j.rmed.2008.11.007"},{"key":"ref159","doi-asserted-by":"publisher","unstructured":"159.     Taveira-DaSilva AM, Johnson SR, Julien-Williams P, Johnson J, Stylianou M, Moss J. Pregnancy in lymphangioleiomyomatosis: clinical and lung function outcomes in two national cohorts. Thorax. 2020;75(10):904-7. https:\/\/doi.org\/10.1136\/thoraxjnl-2020-214987","DOI":"10.1136\/thoraxjnl-2020-214987"},{"key":"ref160","doi-asserted-by":"crossref","unstructured":"160.     Zhou J, Diao M. Lymphangioleiomyomatosis and pregnancy: a mini-review. Arch Gynecol Obstet. 2024;309(6):2239-46. https:\/\/doi.org\/10.1007\/s00404-024-07478-2","DOI":"10.1007\/s00404-024-07478-2"},{"key":"ref161","doi-asserted-by":"publisher","unstructured":"161.     Munshi A, Hyslop AD, Kopras EJ, Gupta N. Spontaneous pneumothoraces during pregnancy in patients with lymphangioleiomyomatosis. Respir Invest. 2023;61(5):632-5. https:\/\/doi.org\/10.1016\/j.resinv.2023.06.006","DOI":"10.1016\/j.resinv.2023.06.006"},{"key":"ref162","doi-asserted-by":"publisher","unstructured":"162.     Wang-Koehler E, Kern-Goldberger AR, Srinivas SK. Complications of lymphangioleiomyomatosis in pregnancy: a case report and review of the literature. AJOG Glob Rep. 2024;4(1):100309. https:\/\/doi.org\/10.1016\/j.xagr.2024.100309","DOI":"10.1016\/j.xagr.2024.100309"},{"key":"ref163","doi-asserted-by":"crossref","unstructured":"163.     Shen L, Xu W, Gao J, Wang J, Huang J, Wang Y, et al. Pregnancy after the diagnosis of lymphangioleiomyomatosis (LAM). Orphanet J Rare Dis. 2021;16(1):133. https:\/\/doi.org\/10.1186\/s13023-021-01776-7","DOI":"10.1186\/s13023-021-01776-7"},{"key":"ref164","doi-asserted-by":"publisher","unstructured":"164.     Champion ML, Maier JG, Bushman ET, Barney JB, Casey BM, Sinkey RG. Systematic review of lymphangioleiomyomatosis outcomes in pregnancy and a proposed management guideline. Am J Perinatol. 2024;41(Suppl 1):e1508-e1520. https:\/\/doi.org\/10.1055\/a-2051-8395","DOI":"10.1055\/a-2051-8395"},{"key":"ref165","doi-asserted-by":"publisher","unstructured":"165.     Iruloh C, Keriakos R, Smith DJ, Cleveland T. Renal angiomyolipoma and lymphangioleiomyomatosis in pregnancy. J Obstet Gynaecol. 2013;33(6):542-6. https:\/\/doi.org\/10.3109\/01443615.2013.812622","DOI":"10.3109\/01443615.2013.812622"},{"key":"ref166","doi-asserted-by":"publisher","unstructured":"166.     Ponticelli C, Moroni G. Fetal toxicity of immunosuppressive drugs in pregnancy. J Clin Med. 2018;7(12):552. https:\/\/doi.org\/10.3390\/jcm7120552","DOI":"10.3390\/jcm7120552"},{"key":"ref167","doi-asserted-by":"publisher","unstructured":"167.     Faehling M, Frohnmayer S, Leschke M, Trinajstic-Schulz B, Weber J, Liewald F. Successful pregnancy complicated by persistent pneumothorax in a patient with lymphangioleiomyomatosis (LAM) on sirolimus. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(2):153-5.","DOI":"10.1055\/s-0030-1251318"},{"key":"ref168","doi-asserted-by":"publisher","unstructured":"168.     Rose M, Ritter D, Gupta N, Tolusso L, Horn P, Wakefield E, et al. Healthcare provider recognition of pregnancy related risks and management considerations in patients with tuberous sclerosis complex. Orphanet J Rare Dis. 2024;19(1):4. https:\/\/doi.org\/10.1186\/s13023-023-03015-7","DOI":"10.1186\/s13023-023-03015-7"},{"key":"ref169","doi-asserted-by":"publisher","unstructured":"169.     Yano S. Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous oestrogen used for infertility treatment. Thorax. 2002;57(12):1085-6. https:\/\/doi.org\/10.1136\/thorax.57.12.1085","DOI":"10.1136\/thorax.57.12.1085"},{"key":"ref170","doi-asserted-by":"publisher","unstructured":"170.     Taylor JR, Ryu J, Colby TV, Raffin TA. Lymphangioleiomyomatosis. Clinical course in 32 patients. N Engl J Med. 1990;323(18):1254-60. https:\/\/doi.org\/10.1056\/NEJM199011013231807","DOI":"10.1056\/nejm199011013231807"},{"key":"ref171","doi-asserted-by":"publisher","unstructured":"171.     Ye L, Jin M, Bai C. Clinical analysis of patients with pulmonary lymphangioleiomyomatosis (PLAM) in mainland China. Respir Med. 2010;104(10):1521-6. https:\/\/doi.org\/10.1016\/j.rmed.2010.05.003","DOI":"10.1016\/j.rmed.2010.05.003"},{"key":"ref172","doi-asserted-by":"publisher","unstructured":"172.     Watanabe EH, Neves PD, Balbo BE, Sampaio CA, Onuchic LF. Giant renal angiomyolipoma following ovarian stimulation therapy. Urology. 2018;112:e3-e4. https:\/\/doi.org\/10.1016\/j.urology.2017.10.039","DOI":"10.1016\/j.urology.2017.10.039"},{"key":"ref173","doi-asserted-by":"publisher","unstructured":"173.     Taveira-Dasilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J. Bone mineral density in lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2005;171(1):61-7. https:\/\/doi.org\/10.1164\/rccm.200406-701OC","DOI":"10.1164\/rccm.200406-701oc"},{"key":"ref174","doi-asserted-by":"publisher","unstructured":"174.     Oprescu N, McCormack FX, Byrnes S, Kinder BW. Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry. Lung. 2013;191(1):35-42. https:\/\/doi.org\/10.1007\/s00408-012-9419-3","DOI":"10.1007\/s00408-012-9419-3"},{"key":"ref175","doi-asserted-by":"publisher","unstructured":"175.     Kitaichi M, Nishimura K, Itoh H, Izumi T. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med. 1995;151(2 Pt 1):527-33. https:\/\/doi.org\/10.1164\/ajrccm.151.2.7842216","DOI":"10.1164\/ajrccm.151.2.7842216"},{"key":"ref176","doi-asserted-by":"publisher","unstructured":"176.     Matsui K, Beasley MB, Nelson WK, Barnes PM, Bechtle J, Falk R, et al. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol. 2001;25(4):479-84. https:\/\/doi.org\/10.1097\/00000478-200104000-00007","DOI":"10.1097\/00000478-200104000-00007"},{"key":"ref177","doi-asserted-by":"publisher","unstructured":"177.     Johnson SR, Cordier JF, Lazor R, Cottin V, Costabel U, Harari S, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010;35(1):14-26. https:\/\/doi.org\/10.1183\/09031936.00076209","DOI":"10.1183\/09031936.00076209"},{"key":"ref178","doi-asserted-by":"publisher","unstructured":"178.     Wahedna I, Cooper S, Williams J, Paterson IC, Britton JR, Tattersfield AE. Relation of pulmonary lymphangioleiomyomatosis to use of the oral contraceptive pill and fertility in the UK: a national case control study. Thorax. 1994;49(9):910-4. https:\/\/doi.org\/10.1136\/thx.49.9.910","DOI":"10.1136\/thx.49.9.910"},{"key":"ref179","doi-asserted-by":"publisher","unstructured":"179.     Chang WY, Cane JL, Blakey JD, Kumaran M, Pointon KS, Johnson SR. Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Respir Res. 2012;13(1):34. https:\/\/doi.org\/10.1186\/1465-9921-13-34","DOI":"10.1186\/1465-9921-13-34"},{"key":"ref180","doi-asserted-by":"crossref","unstructured":"180.     Nunez O, Baldi BG, Radzikowska E, Carvalho CRR, Herranz C, Sobiecka M, et al. Risk of breast cancer in patients with lymphangioleiomyomatosis. Cancer Epidemiol. 2019;61:154-156. https:\/\/doi.org\/10.1016\/j.canep.2019.06.004","DOI":"10.1016\/j.canep.2019.06.004"},{"key":"ref181","doi-asserted-by":"publisher","unstructured":"181.     Torasawa M, Shukuya T, Uemura K, Hayashi T, Ueno T, Kohsaka S, et al. Lymphangioleiomyomatosis as a potent lung cancer risk factor: insights from a Japanese large cohort study. Respirology. 2024;29(9):815-824. https:\/\/doi.org\/10.1111\/resp.14724","DOI":"10.1111\/resp.14724"},{"key":"ref182","doi-asserted-by":"publisher","unstructured":"182.     Revilla-L\u00f3pez E, Ruiz de Miguel V, L\u00f3pez-Meseguer M, Berastegui C, Boada-P\u00e9rez M, Mendoza-Valderrey A, et al. Lymphangioleiomyomatosis: searching for potential biomarkers. Front Med (Lausanne). 2023;10:1079317. https:\/\/doi.org\/10.3389\/fmed.2023.1079317","DOI":"10.3389\/fmed.2023.1079317"},{"key":"ref183","doi-asserted-by":"publisher","unstructured":"183.     Esposito AJ, Imani J, Shrestha S, Bagwe S, Lamattina AM, Vivero M, et al. Lymphangioleiomyomatosis: circulating levels of FGF23 and pulmonary diffusion. J Bras Pneumol. 2023;49(2):e20220356. https:\/\/doi.org\/10.36416\/1806-3756\/e20220356","DOI":"10.36416\/1806-3756\/e20220356"},{"key":"ref184","doi-asserted-by":"publisher","unstructured":"184.     Carthy NM, Franciosi A, Gupta N, Noonan K, Cormack FM, Curran K, et al. Machine Learning to identify novel serum biomarkers in lymphangioleiomyomatosis. European Respiratory Society Congress 2024. A1063. https:\/\/doi.org\/10.1183\/13993003.congress-2024.OA1063","DOI":"10.1183\/13993003.congress-2024.oa1063"},{"key":"ref185","unstructured":"185.     U.S. National Institutes of Health. U.S. National Library of Medicine. ClinicalTrials.gov. [homepage on the Internet]. Bethesda: U.S. National Institutes of Health. Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial (MILED). Available from: https:\/\/clinicaltrials.gov\/study\/NCT03150914"},{"key":"ref186","doi-asserted-by":"publisher","unstructured":"186.     Molina-Molina M. The challenge of therapeutic options for patients with lymphangioleiomyomatosis. Lancet Respir Med. 2024;12(12):938-939. https:\/\/doi.org\/10.1016\/S2213-2600(24)00328-X","DOI":"10.1016\/s2213-2600(24)00328-x"},{"key":"ref187","doi-asserted-by":"publisher","unstructured":"187.     El-Chemaly S, Taveira-DaSilva A, Goldberg HJ, Peters E, Haughey M, Bienfang D, et al. Sirolimus and autophagy inhibition in lymphangioleiomyomatosis: results of a phase I clinical trial. Chest. 2017;151(6):1302-1310. https:\/\/doi.org\/10.1016\/j.chest.2017.01.033","DOI":"10.1016\/j.chest.2017.01.033"},{"key":"ref188","doi-asserted-by":"publisher","unstructured":"188.     Gupta N, Zhang B, Zhou Y, McCormack FX, Ingledue R, Robbins N, et al. Safety and efficacy of combined resveratrol and sirolimus in lymphangioleiomyomatosis. Chest. 2023;163(5):1144-1155. https:\/\/doi.org\/10.1016\/j.chest.2023.01.007","DOI":"10.1016\/j.chest.2023.01.007"},{"key":"ref189","doi-asserted-by":"publisher","unstructured":"189.     Harari S, Elia D, Caminati A, Geginat J, Luisi F, Pelosi G, et al. Nintedanib for patients with lymphangioleiomyomatosis: a phase 2, open-label, single-arm study. Lancet Respir Med. 2024;12(12):967-974. https:\/\/doi.org\/10.1016\/S2213-2600(24)00217-0","DOI":"10.1016\/s2213-2600(24)00217-0"},{"key":"ref190","doi-asserted-by":"publisher","unstructured":"190.     Liu HJ, Krymskaya VP, Henske EP. Immunotherapy for lymphangioleiomyomatosis and tuberous sclerosis: progress and future directions. Chest. 2019;156(6):1062-1067. https:\/\/doi.org\/10.1016\/j.chest.2019.08.005","DOI":"10.1016\/j.chest.2019.08.005"},{"key":"ref191","doi-asserted-by":"publisher","unstructured":"191.     Lu C, Lee HS, Pappas GP, Dilling DF, Burger CD, Shifren A, et al. A phase II clinical trial of an aromatase inhibitor for postmenopausal women with lymphangioleiomyomatosis. Ann Am Thorac Soc. 2017;14(6):919-928. https:\/\/doi.org\/10.1513\/AnnalsATS.201610-824OC","DOI":"10.1513\/annalsats.201610-824oc"},{"key":"ref192","doi-asserted-by":"publisher","unstructured":"192.     Krymskaya VP, Courtwright AM, Fleck V, Dorgan D, Kotloff R, McCormack FX, et al. A phase II clinical trial of the safety of simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex. Respir Med. 2020;163:105898. https:\/\/doi.org\/10.1016\/j.rmed.2020.105898","DOI":"10.1016\/j.rmed.2020.105898"},{"key":"ref193","doi-asserted-by":"publisher","unstructured":"193.     B\u00e4hr S, Rue RW, Smith CJ, Evans JF, K\u00f6ster H, Krymskaya VP, et al. Repurposing Nitazoxanide for potential treatment of rare disease lymphangioleiomyomatosis. Biomolecules. 2024;14(10):1236. https:\/\/doi.org\/10.3390\/biom14101236","DOI":"10.3390\/biom14101236"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T20:46:34Z","timestamp":1738788394000},"score":1,"resource":{"primary":{"URL":"https:\/\/jornaldepneumologia.com.br\/details\/4063\/en-US"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":194,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20240378","relation":{},"ISSN":["1806-3756"],"issn-type":[{"value":"1806-3756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]}}}